Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS In Brief

This article was originally published in The Gray Sheet

Executive Summary

CMS expands coverage of PET for solid tumors: Agency finalizes its coverage reconsideration Aug. 4 on positron emission tomography for solid tumors and myeloma, easing its previous strict limit of one FDG PET study per patient during the initial treatment stages. While CMS will continue to nationally cover only one PET scan to determine the location and/or extent of a tumor for therapeutic purposes related to the initial treatment strategy, local Medicare contractors will now have discretion to determine whether to cover additional PET scans as needed during the initial treatment stage. CMS opened the reconsideration late last year at the request of several radiology and nuclear medicine professional societies (1"The Gray Sheet" Nov. 16, 2009)

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts